Product Launch (Blog)

Sep, 18 2023

Shedding Light on Cellular Mysteries: Unravelling DNA with Fluorescent in Situ Hybridization (FISH)

The Global Fluorescent in Situ Hybridization (FISH) Market is vital in genetics and diagnostics. It employs fluorescently labeled DNA probes to target specific genes or chromosomes within cells, enabling applications such as cancer diagnosis, identifying genetic abnormalities, and studying microorganisms. FISH offers high sensitivity and specificity, allowing for precise genetic analysis. Its benefits include early disease detection, personalized medicine, and improved patient outcomes by tailoring treatments. FISH plays a crucial role in advancing genetic research, clinical diagnostics, and understanding complex biological processes.

According to Data Bridge Market Research, the Global Fluorescent in Situ Hybridization (FISH) Market is expected to reach a value of USD 1,830.55 million by 2030, at a CAGR of 8.2% during the forecast period of 2023-2030.

“Growing burden of genetic disorders as well as cancer boosts the market’s growth”

Genetic abnormalities, while individually rare, collectively account for a significant portion of diseases. Gene alterations underlie cancer development, with only a small percentage being genetically predisposed. Yet, in cases where specific cancer types appear within families, heredity may play a role. Both hematologic and solid cancers exhibit genetic heterogeneity, with numerous genomic abnormalities such as chromosomal fragment alterations and gene mutations contributing to malignancies. Decades of research into genomic instability have highlighted the connection between genetic aberrations and disease. The market for clinical diagnosis of chromosomal abnormalities, including deletions, duplications, and translocations, thrives due to techniques such as FISH and in situ hybridization.

What restraints the growth of the global fluorescent in situ hybridization (FISH) market?

“High cost of FISH testing restraints the market’s growth”

FISH, a macromolecule recognition technique, utilizes DNA or DNA/RNA double strands' complementary nature. It precisely maps genetic material in human cells, identifying specific genes or segments. FISH aids in cancer diagnosis by detecting disease-related genetic abnormalities. Cost considerations are crucial in contemporary molecular diagnostic labs. Automating complex molecular assays not only increases testing capacity but also substantially cuts reagent costs, restraining market growth.

Segmentation: Global Fluorescent in Situ Hybridization (FISH) Market

The global fluorescent in situ hybridization (FISH) market is segmented into six notable segments based on product type, technology, application, usage, end user, and distribution channel.

  • On the basis of product type, the market is segmented into consumables, instrument, and software.
  • On the basis of technology, the market is segmented into DNA fluorescent in situ hybridization, RNA fluorescent in situ hybridization, PNA fluorescent in situ hybridization, and others.
  • On the basis of application, the market is segmented into cancer research, genetic research, infectious disease, personalized medicine, and other.
  • On the basis of shape segment, the electric vehicle charging cables market is segmented into straight cable and coiled cable.
  • On the basis of the usage, the market is segmented into clinical, research, and companion diagnostic.
  • On the basis of the end user, the market is segmented into hospitals and clinics, diagnostic laboratories, pharmaceuticals and biotechnology companies, contract research organizations, academic and research institutes, and others.
  • On the basis of distribution channel, the market is segmented into direct tender, retail sales, online sales, and others.

Regional Insights: North America is expected to dominate the Global Fluorescent in Situ Hybridization (FISH) Market

North America is poised to lead the market, driven by substantial investments in breast cancer and infectious disease research and development. These investments are anticipated to fuel market expansion as innovative treatments and diagnostics emerge. With a strong focus on healthcare innovation and substantial R&D initiatives, the region is well-positioned to advance the field, addressing critical medical needs and propelling market growth.

To know more about the study visit,

Recent Developments

  • In March 2023, Abcam plc. Announced its receipt of the prestigious "Antibody Supplier of the Year" award from CiteAb's annual industry awards. This recognition follows Abcam's recent inclusion in Fast Company's list of the world's most innovative companies, acknowledging its groundbreaking efforts to enhance data reproducibility. The "Antibody Supplier of the Year" award is presented to the provider with the highest antibody product citations in 2022. Additionally, Abcam received a "highly commended" rating in the "Post Translational Modification Antibody Supplier of the Year" category, highlighting its expertise in creating and validating antibodies for challenging targets. These accolades have significantly boosted Abcam's global reputation.
  • In March 2023, BIOZOL Diagnostics Vertrieb GmbH announced the acquisition of AlphaScience GmbH. By making this acquisition, BIOZOL Diagnostics Vertrieb GmbH strengthened its dominant position in the global market for research and diagnostics. With a significant number of new supplier connections, outstanding product knowledge, and staff who are well-trained technically, AlphaScience enhances BIOZOL. Significant synergy effects between the two organizations improving their offerings to customers and suppliers.
  • In July 2022, Bio-Techne announced the launch of the CE-IVD designated RNAscope ISH Probe High Risk HPV in Europe in order to help patients with Oropharyngeal Squamous Cell Carcinoma (OPSCC) identify high-risk Human Papillomavirus (HPV). For the qualitative identification of HPV E6/E7 mRNA in FFPE tissue samples, the RNAscope ISH Probe High Risk HPV is used. This has aided the business in offering better solutions all over the world.

The Prominent Key Players Operating in the Global Fluorescent in Situ Hybridization (FISH) Market Include:

  • Thermo Fisher Scientific Inc. (U.S.)
  • Bio-Techne (U.S.)
  • Abbott (U.S.)
  • Agilent Technologies, Inc. (U.S.)
  • Merck KGaA (Germany)
  • F. Hoffmann-La Roche Ltd (Switzerland)
  • Abnova Corporation (Taiwan)
  • BioDot (U.S.)
  • Biocare Medical, LLC (U.S.)
  • Abcam plc. (U.K.)
  • Sysmex Asia Pacific Pte Ltd (a subsidiary of Sysmex Corporation) (Japan)
  • BIOZOL Diagnostics Vertrieb GmbH (Germany)
  • Zytomed Systems GmbH (Germany)
  • Genemed Biotechnologies, Inc. (U.S.)
  • Bio SB (U.S.)
  • BioGenex (U.S.)
  • Excilone (France)
  • MetaSystems (Germany)
  • Kaneka Eurogentec S.A. (Belgium)
  • BioCat GmbH (Germany)
  • Leica Biosystems Nussloch GmbH (Germany)

Above are the key players covered in the report, to know about more and exhaustive list of global fluorescent in situ hybridization (FISH) market companies contact,

Research Methodology: Global Fluorescent in Situ Hybridization (FISH) Market

Data collection and base year analysis are done using data collection modules with large sample sizes. The market data is analyzed and estimated using market statistical and coherent models. In addition, market share analysis and key trend analysis are the major success factors in the market report. The key research methodology used by DBMR research team is data triangulation which involves data mining, analysis of the impact of data variables on the market, and primary (industry expert) validation. Apart from this, data models include Vendor Positioning Grid, Market Time Line Analysis, Market Overview and Guide, Company Positioning Grid, Company Market Share Analysis, Standards of Measurement, Global vs Regional and Vendor Share Analysis. Please request analyst call in case of further inquiry.

Client Testimonials